Gurumurthy Srividya 1 , Narayanasamy Angayarkanni 2 , Geetha Iyer 3 , Bhaskar Srinivasan 4 , Shweta Agarwal 4 . Show Affiliations »
Abstract
BACKGROUND: Stevens-Johnson syndrome (SJS), a blistering disorder of the skin and mucous membrane, leads to ocular morbidity in >60% of cases. Retinoids are vital micronutrients for vision, regulating corneal and conjunctival cell proliferation, differentiation and immune function. This prospective case-control study probed for alterations in retinoid metabolism by evaluating retinoic acid receptor signalling in the conjunctival cells of patients with SJS. METHODS: Imprints were collected from the bulbar conjunctiva of patients with chronic SJS. The gene expression of retinoic acid receptors, namely, RXRA, RARA, RARG, RORA; the fibrosis marker TGFβ and its receptor TGFβRII; the transcription factors PPAR-γ, STRA6 and Stat3; the enzymes aldehyde dehydrogenase (ALDH1a1), alpha-1 antitrypsin (A1AT); and the Cyp genes Cyp26a1 and Cyp26b1 were assessed by quantitative PCR in patients with SJS pre-mucous (n = 34) and post-mucous membrane graft (MMG) intervention (n=19) in comparison with age-matched/sex-matched healthy controls (n=20). Western blot analysis of ALDH1a1, RARA and RARG were done in the conjunctival imprint cells. RESULTS: The transcript levels of ALDH1a1, RXRA, RORA, STRA6, Cyp26a1 and Cyp26b1 were decreased around 4, 26, 17, 129, 9 and 8 folds, respectively, and RARA, RARG, PPAR-γ, TGFβ, TGFβRII were increased by 12, 15, 51, 16 and 87 folds, respectively, in SJS conjunctiva at the pre-MMG stage. The changes in RORA, Cyp26a1, Cyp26b1, RARA and Stat3 were statistically significant (p<0.05). Changes in protein expression of ALDH1a1, RARA and RARG supported the gene expression changes. CONCLUSIONS: The study provides the first experimental insight into the role of retinoid metabolism in the ocular sequelae of chronic SJS. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.
BACKGROUND: Stevens-Johnson syndrome (SJS ), a blistering disorder of the skin and mucous membrane, leads to ocular morbidity in >60% of cases. Retinoids are vital micronutrients for vision, regulating corneal and conjunctival cell proliferation, differentiation and immune function. This prospective case-control study probed for alterations in retinoid metabolism by evaluating retinoic acid receptor signalling in the conjunctival cells of patients with SJS . METHODS: Imprints were collected from the bulbar conjunctiva of patients with chronic SJS . The gene expression of retinoic acid receptors, namely, RXRA , RARA , RARG , RORA ; the fibrosis marker TGFβ and its receptor TGFβRII; the transcription factors PPAR-γ, STRA6 and Stat3 ; the enzymes aldehyde dehydrogenase (ALDH1a1 ), alpha-1 antitrypsin (A1AT ); and the Cyp genes Cyp26a1 and Cyp26b1 were assessed by quantitative PCR in patients with SJS pre-mucous (n = 34) and post-mucous membrane graft (MMG) intervention (n=19) in comparison with age-matched/sex-matched healthy controls (n=20). Western blot analysis of ALDH1a1 , RARA and RARG were done in the conjunctival imprint cells. RESULTS: The transcript levels of ALDH1a1 , RXRA , RORA , STRA6 , Cyp26a1 and Cyp26b1 were decreased around 4, 26, 17, 129, 9 and 8 folds, respectively, and RARA , RARG , PPAR-γ, TGFβ, TGFβRII were increased by 12, 15, 51, 16 and 87 folds, respectively, in SJS conjunctiva at the pre-MMG stage. The changes in RORA , Cyp26a1 , Cyp26b1 , RARA and Stat3 were statistically significant (p<0.05). Changes in protein expression of ALDH1a1 , RARA and RARG supported the gene expression changes. CONCLUSIONS: The study provides the first experimental insight into the role of retinoid metabolism in the ocular sequelae of chronic SJS . © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.
Entities: Chemical
Disease
Gene
Species
Keywords:
ALDH1; SJS; Stevens-Johnson syndrome; ocular SJS; retinaldehyde; retinoic acid; retinoids; vitamin A
Mesh: See more »
Substances: See more »
Year: 2019
PMID: 31023710 DOI: 10.1136/bjophthalmol-2018-312849
Source DB: PubMed Journal: Br J Ophthalmol ISSN: 0007-1161 Impact factor: 4.638